[Potential of PET in the diagnosis and the assessment of treatment effectiveness in progressive malignant glioma].

Examination including MRI (CT), PET with sodium 11C-butyrate (11C-SB) and 18fluorodeoxyglucose (18F-FDG) was carried out in 59 patients with continuing growth of malignant glioma. It was established that 11C-SB-PET is characterized by high sensitivity (94.1%) in detecting continuing growth as well as to differentiating it from necrosis.